Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20-positive Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03019055
What this trial is testing

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, B-CellChronic Lymphocytic Leukemia+1 more
Medical College of Wisconsin 26
Testing effectiveness (Phase 2)Looking for participantsNCT06021678
What this trial is testing

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Who this might be right for
CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc. 415
Early research (Phase 1)Ended earlyNCT01370694
What this trial is testing

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Who this might be right for
Follicular Lymphoma
Merck Sharp & Dohme LLC 7
Early research (Phase 1)Not Yet RecruitingNCT07043218
What this trial is testing

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine 36
Testing effectiveness (Phase 2)WithdrawnNCT03169790
What this trial is testing

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Who this might be right for
Non Hodgkin Lymphoma
ImmunityBio, Inc.
Testing effectiveness (Phase 2)UnknownNCT04425824
What this trial is testing

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell LymphomaRituximabToripalimab
Chinese Academy of Medical Sciences 20
Early research (Phase 1)UnknownNCT03980379
What this trial is testing

Pharmacokinetics, Efficacy and Safety of the 304 Injection

Who this might be right for
CD20 Positive B Cell NHL
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 60
Early research (Phase 1)Looking for participantsNCT07073833
What this trial is testing

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Imbioray (Hangzhou) Biomedicine Co., Ltd. 40
Testing effectiveness (Phase 2)UnknownNCT00397800
What this trial is testing

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Technical University of Munich 12
Large-scale testing (Phase 3)Study completedNCT01459887
What this trial is testing

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma
Shanghai CP Guojian Pharmaceutical Co., Ltd. 278
Early research (Phase 1)Ended earlyNCT03670888
What this trial is testing

Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Who this might be right for
B Cell Lymphoma
JHL Biotech, Inc. 1
Early research (Phase 1)Ended earlyNCT06248086
What this trial is testing

Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Who this might be right for
B-cell Lymphoma
Astellas Pharma Global Development, Inc. 1
Early research (Phase 1)Ended earlyNCT02483000
What this trial is testing

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Who this might be right for
Burkitt LymphomaCD20-Positive Neoplastic Cells PresentDiffuse Large B-Cell Lymphoma+4 more
Fred Hutchinson Cancer Center 3
Early research (Phase 1)Study completedNCT01729806
What this trial is testing

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
CD20 PositiveRecurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Study completedNCT03458260
What this trial is testing

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation 74
Testing effectiveness (Phase 2)Ended earlyNCT05348889
What this trial is testing

First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

Who this might be right for
Non-Hodgkin's Lymphoma (disorder)Acute Lymphoid Leukemia, Disease (disorder)
Chimagen Biosciences, Ltd 7
Early research (Phase 1)Temporarily pausedNCT04746131
What this trial is testing

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 90
Early research (Phase 1)UnknownNCT06364852
What this trial is testing

An Evaluation of LY007 Cell Injection for r/r B-NHL

Who this might be right for
B-NHL
Ruijin Hospital 18
Early research (Phase 1)Ended earlyNCT05987605
What this trial is testing

Phase I/II Clinical Study of 1A46 Drug Substance

Who this might be right for
Advanced Malignancies
BioRay Pharmaceutical Co., Ltd. 4
Testing effectiveness (Phase 2)Study completedNCT02584920
What this trial is testing

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

Who this might be right for
B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech 87
Next Page